Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Picking the endpoints

It is not possible to directly demonstrate an HPV vaccine's ability to prevent cervical cancer because it takes decades for infection to cause cancer, and the standard of care is to screen for and excise precancerous lesions. Merck & Co. Inc. and GlaxoSmithKline plc took different approaches to get around this issue.

Given the problem in showing direct clinical efficacy, FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) issued recommendations to FDA on efficacy endpoints for HPV vaccines in November 2001.

Read the full 814 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE